HER-TEMPO - Real World Treatment-related Outcomes on T-DXd in Canada

Clinical trial NCT06386263 · COMPLETED

Trial details

NCT number: NCT06386263
Sponsor: AstraZeneca
Status: COMPLETED
Study type: OBSERVATIONAL

Unresectable Breast Cancer Metastatic Breast Cancer HER2-low Expressing Breast Cancer HER2-positive Breast Cancer

Start date: 2024-04-22
Primary completion: 2025-07-07
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.